Skip to content
Subscribe Follow on LinkedIn

Press Release

Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease

Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease

✨ Onyx Summary Alzheon announced the peer-reviewed publication of results from its pivotal Phase 3 APOLLOE4 trial evaluating oral valiltramiprosate (ALZ-801) in APOE4/4 homozygous individuals with early Alzheimer’s disease, showing cognitive and functional benefits in patients at the mild cognitive impairment stage, along with neuroprotective effects on brain atrophy

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal’s Sellersville, Pennsylvania Site

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal’s Sellersville, Pennsylvania Site

✨ Onyx Summary Piramal Pharma Solutions and NewAmsterdam Pharma announced a multi-million-dollar investment to establish a dedicated oral solid dosage suite at Piramal’s Sellersville, Pennsylvania site, enhancing production capacity for NewAmsterdam’s fixed-dose combination of obicetrapib and ezetimibe. The initiative expands Piramal’s integrated CDMO network, supports future commercial demand

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

✨ Onyx Summary Lexicon Pharmaceuticals presented new Phase 2 analyses for pilavapadin (LX9211) at the 19th Annual Pain Therapeutics Summit, confirming the 10 mg once-daily dose as the optimal candidate for Phase 3 development in diabetic peripheral neuropathic pain (DPNP). The findings—demonstrating validated biological activity, clinically meaningful pain reduction, and

Affinia Therapeutics to Participate in Upcoming Investor Conferences

Affinia Therapeutics to Participate in Upcoming Investor Conferences

✨ Onyx Summary Affinia Therapeutics CEO Rick Modi will participate in a panel on in vivo gene therapies for genetic cardiac diseases at Chardan’s 9th Annual Genetic Medicines Conference on Oct. 21 and hold one-on-one investor meetings at the Jefferies Global Healthcare Conference in London on Nov. 17–20. The

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

✨ Onyx Summary Rocket Pharmaceuticals announced that the U.S. FDA has accepted its resubmitted BLA for KRESLADI™ (marnetegragene autotemcel; marne-cel), an investigational gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I), setting a PDUFA date of March 28, 2026. The filing is supported by Phase 1/2 data showing 100% survival

Verily, UCHealth, University of Colorado Anschutz, and RefinedScience launch strategic collaboration for AI-powered research and care transformation

Verily, UCHealth, University of Colorado Anschutz, and RefinedScience launch strategic collaboration for AI-powered research and care transformation

✨ Onyx Summary Verily has entered a multi-year strategic collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience to advance precision medicine through AI-driven data integration and analytics on Verily’s healthcare technology platform. The partnership will create AI-ready biomedical data pipelines, develop novel models across major therapeutic areas, and

Geron Corporation Announces Executive Leadership Transitions and Appointments

Geron Corporation Announces Executive Leadership Transitions and Appointments

✨ Onyx Summary Geron Corporation announced multiple leadership changes to align with its commercial growth strategy, including the appointment of Ahmed ElNawawi as EVP and Chief Commercial Officer, alongside new senior hires in technical operations, investor relations, and portfolio management. These appointments strengthen Geron’s leadership capabilities as it drives commercialization

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025

✨ Onyx Summary Seer, Inc. announced its participation at the 2025 American Society of Human Genetics Annual Meeting, where it will showcase how its Proteograph® Product Suite enables integration of proteomics and genomics to advance precision medicine. The company will host a featured CoLab session and support multiple scientific presentations demonstrating

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

✨ Onyx Summary Rocket Pharmaceuticals granted inducement equity awards to newly appointed Chief Medical Officer Dr. Syed Rizvi, consisting of stock options and restricted stock units totaling approximately 729,765 shares. The awards, approved under Nasdaq’s inducement grant rule, align long-term incentives with Rocket’s strategic growth as it advances

Aspect Biosystems to Present at 2025 Cell & Gene Meeting on the Mesa

Aspect Biosystems to Present at 2025 Cell & Gene Meeting on the Mesa

✨ Onyx Summary Aspect Biosystems Chief Scientific Officer Sam Wadsworth will present at the 2025 Cell & Gene Meeting on the Mesa on October 7 in Phoenix, highlighting the company’s advancements in regenerative medicine. The annual conference, organized by the Alliance for Regenerative Medicine, gathers global leaders in cell and

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society

✨ Onyx Summary Avidity Biosciences will present new one-year data on delpacibart zotadirsen (del-zota) for Duchenne muscular dystrophy (DMD44) at the 30th Annual World Muscle Society Congress, showing reversal of disease progression and improvements across functional measures from its EXPLORE44® and EXPLORE44-OLE™ trials. The presentations, featuring leading clinicians, reinforce del-zota’s

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

✨ Onyx Summary Phathom Pharmaceuticals appointed Sanjeev Narula as Chief Financial and Business Officer, bringing over two decades of financial leadership experience from Intra-Cellular Therapies, Viatris, and Pfizer. His appointment strengthens Phathom’s executive team as the company advances commercialization of its GI franchise, VOQUEZNA, and pursues its strategy toward profitability